Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07684313 · ClinicalTrials.gov registry record
TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)
A clinical trial, sponsored by Edwards Lifesciences.
- Not yet
- Registry status
- 75
- Enrollment target
NCT07684313 is a clinical trial that has not yet begun recruiting, run by Edwards Lifesciences. The registered enrollment target is 75 participants.
The verdict
NCT07684313 has not yet begun recruiting, sponsored by Edwards Lifesciences.
- NOT YET RECRUITING
- Registry status
- 75 participants
- Enrollment target
Study Summary
TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.
Interventions
- DEVICE Edwards TRIFORMIS RESILIA heart valve
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-08 |
| Est. Completion | 2034-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07684313
The ClinicalTrials.gov registry entry for NCT07684313 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Edwards TRIFORMIS RESILIA heart valve is the first listed.
NCT07684313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07684313 about?
NCT07684313 is a clinical study titled "TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)". TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.
What is the current status of trial NCT07684313?
This trial is currently not yet recruiting. The enrollment target is 75 participants. The study started on 2026-08. Estimated completion is 2034-12.
What interventions are being tested in trial NCT07684313?
The interventions under investigation include: Edwards TRIFORMIS RESILIA heart valve (DEVICE).
Who is sponsoring clinical trial NCT07684313?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.